Infinity Pharmaceuticals | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Infinity Pharmaceuticals

An SI Board Since April 2006

Posts	SubjectMarks	Bans	Symbol
210	13	0	INFI

Emcee: dr.praveen	Type: Moderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
135	Well, for the moment they seem to be staying out of each other's way. I hop	Mike McFarland	-	11/19/2006
134	>>The course of treatment for refractory GIST is shorter than myeloma?<	tuck	-	11/19/2006
133	That's a good question. I had Kosan on my research back burner until recent	tuck	-	11/19/2006
132	Do you think there are any patent/orphan rights with kosn that are causing infi	rkrw	-	11/19/2006
131	The course of treatment for refractory GIST is shorter than myeloma? fwiw, Infi	Mike McFarland	-	11/19/2006
130	"Are you saying I write incomprehensibly or that the abstracts I post are a	idos	-	11/19/2006
129	Are you saying I write incomprehensibly or that the abstracts I post are a chall	tuck	-	11/19/2006
128	In the latest Nature biotech's paper on HSP90, nothing great though but it s	dr.praveen	-	11/18/2006
127	I'm reading Tuck's posts and hope to understand the main point before th	idos	-	11/18/2006
126	I see from the CC transcript that Infinity hasn't seen good activity in MM w	tuck	-	11/18/2006
125	An update to my post: Kosan Presents Encouraging Antitumor And Safety Data On N	dr.praveen	-	11/17/2006
124	This is from one of my earlier posts: I like Kosan too. Low valuation of 150M$	dr.praveen	-	11/17/2006
123	Combo of Hsp90 inhibitors with other drugs is indeed where it's at; I doubt	tuck	-	11/17/2006
122	Tuck has been posting abstracts on the Kosan thread if you're interested in	Mike McFarland	-	11/17/2006
121	The scientific foundation of this company looks very strong and their alliances,	idos	-	11/17/2006
120	'very early' stage is overstating it, and 'the price is quite dear&	Mike McFarland	-	11/16/2006
119	It might be a bit expensive but that doesn't bother me much. I like the nove	dr.praveen	-	11/16/2006
118	Thanks. Just started to look in to the company, very early stage and the price i	idos	-	11/16/2006
117	Quick note...on the road Nothing much happening until 2nd half 2007 and Multipl	dr.praveen	-	11/16/2006
116	Any idea what made the fall i see now about 10%?	idos	-	11/16/2006
115	Infinity Announces Third Quarter 2006 Results and Highlights Recent Accomplishme	Mike McFarland	-	11/9/2006
114	Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride	tnsaf	-	11/8/2006
113	Infinity and MedImmune Announce Promising Biological Activity of Anti-Hsp90 Comp	nigel bates	-	11/7/2006
112	I liked the starting of the presentation when they were comparing nexavar and su	dr.praveen	-	10/21/2006
111	In the BIO presentation, something was said about infi/medi possibly choosing a	Mike McFarland	-	10/21/2006

Go to reply# or date (mm/dd/yy):